Redeye is encouraged to see the progress made by Scandinavian ChemoTech in the Q3 2023 report, which showed increasing sales and better than expected cost control. However, we emphasize the need for additional financing in the near term and reconsider our estimates following a case overview.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Scandinavian ChemoTech - Financing required

© Modular Finance, source Nordic Press Releases